Propanc Biopharma, Inc. (OTCMKTS:PPCB) Sees Significant Growth in Short Interest

Propanc Biopharma, Inc. (OTCMKTS:PPCB) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totalling 1,884,500 shares, a growth of 21.6% from the August 31st total of 1,550,100 shares. Based on an average trading volume of 5,637,300 shares, the short-interest ratio is presently 0.3 days.

Propanc Biopharma Price Performance

OTCMKTS PPCB remained flat at $0.00 during midday trading on Friday. The company’s stock had a trading volume of 8,528,065 shares, compared to its average volume of 4,651,966. Propanc Biopharma has a 52-week low of $0.00 and a 52-week high of $0.03.

Propanc Biopharma Company Profile

Propanc Biopharma, Inc, a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.